The dynamics of the main epidemiological indicators among living in Moscow patients with diabetes mellitus (2013–2018)

BACKGROUND: State Register of Diabetes Mellitus (SRDM) plays an important role in the dynamic analysis of the epidemiological parameters that evaluate the disease itself and its complications, and also helps to analyze the quality of specialized medical care for patients. To solve modern scientific and practical problems, it is important to analyze data not only among the entire population of Russia, but also in large administrative-territorial subjects of the country.

AIMS: To Study the dynamics of the main epidemiological indicators (values) among patients with type 1 diabetes mellitus (DM1) and type 2 diabetes mellitus (DM2) living in Moscow for the period from 2013 to 2018 according to the State Register of Diabetes Mellitus (SRDM).

MATERIALS AND METHODS: The analysis of Moscow region of the SRDM database was conducted. According to it there were registered 345.1 thousand patients with diabetes by 01.01.2019.

RESULTS: During the period from 2013 to 2018 the total number of patients with DM increased up 9.8% (from 314.4 thousand to 345.1 thousand people). DM2 accounts for 94% of the total number of patients.

According to SRDM the prevalence of DM1 on 100 thousand population has grown up 6.9% (from 152.2 in 2013 to 162.7 in 2018); DM2 – by 9.6% (from 2864.7 in 2013 to 3139.4 in 2018). The incidence of DM1 per 100 thousand people decreased down to 6.4% (from 4.7 in 2013 to 4.4% in 2018); DM2 – grew up 4.3% (from 198.1 in 2002, to 206.6 in 2018).

Throughout the study period the incidence of DM2 was higher among women, while the opposite trend was observed among women with DM1. The mortality among people with DM1 in 2018 was 1.6 per 100 thousand among adult population (in 2017 it was 1.7); among patients with DM2 the mortality was 56.6 people per 100 thousand among adult population (in 2017 it was 65.6).

The first place among the direct causes of death among patients with DM1 and DM2 in 2018 was occupied by cardiovascular diseases (57.5% and 67.9%, respectively), the second place – oncological diseases (9.9% and 12.2%).

CONCLUSIONS: The results of the epidemiological analysis showed that since 2013 in Moscow there has been an increase in the prevalence of diabetes, against the background of stable indicators of incidence (except for the organizational period of adapting to the new online data entry system of SRDM). The leading causes of death of patients with diabetes are cardiovascular and oncological diseases.

diabetes mellitus, epidemiology, prevalence, incidence, mortality, State Register of Diabetes Mellitus

1. Сахарный диабет: диагностика, лечение, профилактика / Под ред. И.И. Дедова, М.В. Шестаковой. — М.: Медицинское информационное агентство, 2011. — 801 с. [Sakharnyi diabet. Diagnostika, lechenie, profilaktika. Ed by I.I. Dedov, M.V. Shestakova. Moscow: Meditsinskoe informatsionnoe agentstvo; 2011. 801 р. (In Russ.)]

2. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 8-й вып. // Сахарный диабет. — 2017. — Т. 20. — №1S. — C. 1–121. [Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Ed. by Dedov II, Shestakova MV, Mayorov AYu. 8th edition. Diabetes mellitus. 2017;20(1S):1–121. (In Russ.)] doi: https://doi.org/10.14341/DM20171s8

3. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines — Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation. 2009;119(1):107–115. doi: https://doi.org/10.1161/CIRCULATIONAHA.108.783688

4. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices primary results of the registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122(6):585–596. doi: https://doi.org/10.1161/CIRCULATIONAHA.109.934471

5. Bradley EH, Herrin J, Wang Y, et al. Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction. JAMA. 2004;292(13):1563–1572. doi: https://doi.org/10.1001/jama.292.13.1563

6. Barron HV, Bowlby LJ, Breen T, et al. Use of reperfusion therapy for acute myocardial infarction in the United States Data from the National Registry of Myocardial Infarction. Circulation. 1998;97(12):1150–1156. doi: https://doi.org/10.1161/01.cir.97.12.1150

7. Gibson CM, Pride YB, Frederick PD, et al. Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J. 2008;156(6):1035–1044. doi: https://doi.org/10.1016/j.ahj.2008.07.029

8. Hoque DM, Kumari V, Hoque M, et al. Impact of clinical registries on quality of patient care and clinical outcomes: a systematic review. PLoS One. 2017;12(9):e0183667. doi: https://doi.org/10.1371/journal.pone.0183667

9. McNeil JJ, Evans SM, Johnson NP, Cameron PA. Clinical-quality registries: their role in quality improvement. Med J Aust. 2010;192(5):244−245. doi: https://doi.org/10.1111/j.1445-5994.2009.02068.x

10. Larsson S, Lawyer P, Garellick G, et al. Use of 13 disease registries in 5 countries demonstrates the potential to use outcome data to improve health care’s value. Health Aff (Millwood). 2012;31(1):220−227. doi: https://doi.org/10.1377/hlthaff.2011.0762

11. Lyu H, Cooper M, Patel K, et al. Prevalence and data transparency of national clinical registries in the United States. J Healthc Qual. 2016;38(4):223−234. doi: https://doi.org/10.1097/JHQ.0000000000000001

12. Приказ Минздрава РФ от 19.08.1993 № 197 «О разработке и создании Автоматизированной информационной системы Государственного регистра больных сахарным диабетом». [Federal Law of Russian Federation № 197 «O razrabotke i sozdanii Avtomatizirovannoi informatsionnoi sistemy Gosudarstvennogo registra bol’nykh sakharnym diabetom», dated 1993 August 19. (In Russ.)] Доступно по: https://www.lawmix.ru/med/17149. Ссылка активна на 21.12.2019.

13. Дедов И.И., Шестакова М.В., Сунцов Ю.И., и др. Результаты реализации подпрограммы «Сахарный диабет» Федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями 2007−2012 годы» // Сахарный диабет. — 2013. — Т. 16. — №2S. — С. 1−48. [Dedov II, Shestakova MV, Suntsov YI, et al. Federal targeted programme «Prevention and Management of Socially Significant Diseases (2007–2012)»: results of the «Diabetes mellitus» sub-programme. Diabetes mellitus. 2013;16(2S):1−48. (In Russ.)] doi: https://doi.org/10.14341/2072-0351-3879

14. Дедов И.И. Сахарный диабет в Российской Федерации: проблемы и пути решения // Сахарный диабет. — 1998. — Т. 1. — №1. — C. 7−18. [Dedov II. Sakharnyi diabet v Rossiiskoi Federatsii: problemy i puti resheniya. Diabetes mellitus. 1998;1(1):7−18. (In Russ.)] doi: https://doi.org/10.14341/2072-0351-6209

15. Дедов И.И., Шестакова М.В., Викулова О.К. Государственный регистр сахарного диабета в Российской Федерации: статус 2014 г. и перспективы развития // Сахарный диабет. — 2015. — Т. 18. — №3. — C. 5−22. [Dedov II, Shestakova MV, Vikulova OK. National register of diabetes mellitus in Russian Federation. Diabetes mellitus. 2015;18(3):5−22. (In Russ.)] doi: https://doi.org/10.14341/DM201535-22

16. Дедов И.И., Шестакова М.В., Викулова О.К., и др. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. // Сахарный диабет. — 2018. — Т. 21. — №3. — С. 144−159. [Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017. Diabetes mellitus. 2018;21(3):144−159. (In Russ.)] doi: https://doi.org/10.14341/DM9686

17. Приказ Минздрава России от 31 января 2014 г. № 52н «О мерах, направленных на обеспечение выполнения Министерством здравоохранения Российской Федерации обязанностей, предусмотренных Федеральным законом от 27 июля 2006 г. № 152-ФЗ «О персональных данных» и принятыми в соответствии с ним нормативными правовыми актами» [Federal Law of Russian Federation № 52n «O merakh, napravlennykh na obespechenie vypolneniya Ministerstvom zdravookhraneniya Rossiiskoi Federatsii obyazannostei, predusmotrennykh Federal’nym zakonom ot 27 iyulya 2006 g. № 152-FZ «O personal’nykh dannykh» i prinyatymi v sootvetstvii s nim normativnymi pravovymi aktami», dated 2014 January 31. (In Russ.)] Доступно по: https://www.rosminzdrav.ru/documents/8034-o-merah-napravle152-fz-o-personalnyh-dannyh-i-prinyatymi-v-. Ссылка активна на 21.12.2019

18. Сайт о странах, городах, статистике населения и пр. [интернет]. Население России: численность, динамика, статистика. [Sayt o stranakh, gorodakh, statistike naseleniya i pr. [Internet]. Naseleniye Rossii: chislennost’, dinamika, statistika. (In Russ.)] Доступно по: http://www.statdata.ru/russia. Ссылка активна на 21.04.2020.

19. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета // Сахарный диабет. — 2017. — Т. 20. — №1. — C. 13−41. [Dedov II, Shestakova MV, Vikulova OK. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry. Diabetes mellitus. 2017;20(1):13−41. (In Russ.)] doi: https://doi.org/10.14341/DM8664

20. Дедов И.И., Калашникова М.Ф., Белоусов Д.Ю., и др. Анализ стоимости болезни сахарного диабета 2 типа в Российской Федерации: результаты Российского многоцентрового наблюдательного фармакоэпидемиологического исследования ФОРСАЙТ-СД2 // Сахарный диабет. — 2017. — Т. 20. — №6. — C. 403−419. [Dedov II, Kalashnikova MF, Belousov DY, et al. Cost-of-illness analysis of type 2 diabetes mellitus in the Russian Federation: results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-Т2DM). Diabetes mellitus. 2017;20(6):403−419. (In Russ.)] doi: https://doi.org/10.14341/DM9278